Demyelinating events associated with IBD therapy are uncommon, with data from large registries and population-based cohorts suggesting an absolute risk of fewer than 1 per 1000 patients exposed to anti-TNF-α blockers.86 Here, TNF is linked to inflammatory bowel disease.